Tobacco-related cancer: How does it happen?

August 30, 2005

WASHINGTON, Aug. 30 -- How does tobacco trigger the more than 170,000 cases of lung cancer that have already been diagnosed this year? While nearly 90 percent of them involved smokers, according to research estimates, only about 25 percent of all smokers are said to develop lung cancer. Why? What disposes some and spares others?

Researchers will discuss these types of questions and share new biochemical and epidemiologic studies, review key findings, and discuss lingering issues in a special symposium: "Tobacco Carcinogenesis," on Tuesday, Aug. 30, during the American Chemical Society's 230th national meeting in Washington, D.C. The symposium will be held at the Renaissance Washington Hotel, East Ballroom, from 8:00 a.m. to noon.

Stephen S. Hecht, Ph.D., head of cancer prevention at the University of Minnesota Cancer Center, and Trevor M. Penning, Ph.D., a professor of pharmacology and principal investigator of a program project on carcinogenesis at the University of Pennsylvania, organized the symposium, which includes scientists from academia, government and industry. Highlights include:

An overview of tobacco carcinogenesis -- What are the major classes of tobacco carcinogens? How might these compounds lead to cancer? As the symposium proceeds, researchers will explore specific tobacco cancer biochemistry in greater detail. For instance, Professor Penning will discuss the ways in which one variety of carcinogenic compounds -- polycyclic aromatic hydrocarbons -- may form lesions in DNA, which can lead to gene mutations that allow cancer cells to emerge and grow unchecked. (TOXI 30, Tuesday, Aug. 30, 8:00 a.m.)

Epidemiology of tobacco-related cancer -- Scientists estimate that only 25 percent of smokers develop lung cancer. Why do some smokers escape the disease, while others die from it? To find out, Peter G. Shields, M.D., director of cancer genetics and epidemiology at Georgetown University's Lombardi Comprehensive Cancer Center, is conducting clinical studies to assess individual differences in response to tobacco carcinogens. Shields will present recent data on this effort. In another epidemiological talk, Mimi Yu, Ph.D., a professor at the University of Minnesota Cancer Center, will report on recent studies of a known bladder carcinogen found in smokers. (TOXI 35 & TOXI 36, Tuesday, Aug. 30, 9:40 a.m. & 10:00 a.m.)

Panel discussion -- A diverse group of scientists, including academic researchers, a government scientist, two tobacco industry researchers from Philip Morris and an independent industry consultant, will provide different perspectives on critical issues facing the field of tobacco-associated cancers. What are the most important carcinogens in tobacco products? How would their reduction/elimination impact cancer mortality among people who continue to smoke? What's the best way to evaluate a tobacco product's carcinogenic potential? (Tuesday, Aug. 30, 10:40 a.m.)

The American Chemical Society is a nonprofit organization, chartered by the U.S. Congress, with a multidisciplinary membership of more than 158,000 chemists and chemical engineers. It publishes numerous scientific journals and databases, convenes major research conferences and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio.
-end-


American Chemical Society

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.